Drug Trial Radar · NCT05099549
Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers
Last checked: Nov 19, 2026Latest source record: Mar 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
11
Actual
Start
Nov 3, 2021
Primary completion
Sep 21, 2023
Study completion Sep 21, 2023
Sponsor
- Lead sponsor
- NKGen Biotech, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Affimed GmbH
- First posted
- Oct 29, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multi-center study to evaluate the safety, tolerability, and anti-tumor activity of SNK01 in combination with AFM24 in subjects with advanced or metastatic EGFR-expressing cancers.
Conditions
- Squamous Cell Carcinoma of Head and Neck
- Carcinoma, Non-Small-Cell Lung
- Colorectal Neoplasms
- Advanced Solid Tumor
- Refractory Tumor
- Metastatic Tumor
Interventions
AFM24Drug
Tetravalent, bispecific EGFR- and CD16A-binding innate cell engager.
SNK01Biological
Patient-specific ex-vivo expanded autologous natural killer cells.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1/Dose EscalationTime frame: 28 days starting on cycle 1 day 1
- Phase 1/Dose EscalationTime frame: 28 days starting on cycle 1 day 1
- Phase 2a/ExpansionTime frame: Up to 24 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
USC/Norris Comprehensive Cancer Center
Los Angeles, California
Sarcoma Oncology Center
Santa Monica, California
University of Chicago
Chicago, Illinois
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.